Platforms for Personalized Polytherapeutics Discovery in COVID-19. Issue 10 (14th May 2021)

• Record Type: Journal Article
• Authors: Hopkins, Christopher; Onweni, Chidinma; Zambito, Victoria; Fairweather, DeLisa; McCormick, Kathryn; Ebihara, Hideki; Caulfield, Thomas; Zhang, Yu Shrike; Freeman, W. David
• Is Part Of: Journal of molecular biology. Volume 433:Issue 10(2021)
• Publication Date: 2021-05-14
• Subjects: COVID-19 -- SARS-CoV -- antiviral -- combination therapy -- ACE2; Molecular biology -- Periodicals; Biology -- Periodicals; Biochemistry -- Periodicals; Bacteriology -- Periodicals; Molecular Biology -- Periodicals; Biochemistry -- Periodicals; Biologie moléculaire -- Périodiques; Biologie -- Périodiques; Biochimie -- Périodiques; Moleculaire biologie; Biochemistry; Biology; Molecular biology; Periodicals; 572.805
• DOI: 10.1016/j.jmb.2021.166945
• Languages: English
• ISSNs: 0022-2836

Abstract

Graphical abstract: Highlights: Society continues to struggle worldwide with COVID-19 infection. Combination therapies like polytherapeutics may help alleviate the societal burden. Alternative model systems enable rapid polytherapy development. Abstract: The COVID-19 pandemic entered its third and most intense to date wave of infections in November 2020. This perspective article describes how combination therapies (polytherapeutics) are a needed focus for helping battle the severity of complications from SARS-CoV-2 infection. It outlines the types of systems that are needed for fast and efficient combinatorial assessment of therapeutic candidates. Proposed are micro-physiological systems using human iPSC as a format for tissue-specific modeling of infection, the use of gene-humanized zebrafish and C. elegans for combinatorial drug screens due to the animals being addressable in liquid multi-well formats, and the use of engineered pseudo-typing systems to safely model infection in the transgenic animals and engineered tissue systems.